Advisory Services Network’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Advisory Services Network’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-62	Closed	-$5.64K	–	3914
2023 Q1	$5.64K	Hold	62	–	–	﹤0.01%	3118
2022 Q4	$2.35K	Buy	+62	New	+$2.13K	﹤0.01%	3386
2021 Q3	–	Sell	-2,188	Closed	-$310K	–	3447
2021 Q2	$310K	Buy	+2,188	New	+$247K	0.01%	1075

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advisory Services Network's RETA Position: Q2 2023 in Review

Advisory Services Network sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 62 shares — an estimated $5.64K sold.

Advisory Services Network first reported a position in RETA in Q2 2021 and held it in 3 quarters. The position peaked at $310K in Q2 2021. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Advisory Services Network reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Advisory Services Network sold 62 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $5.64K.
Advisory Services Network first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2021 and held it in 3 quarters.
Advisory Services Network's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $310K in Q2 2021.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Advisory Services Network's 13F filing for Q2 2023, filed 9 Aug 2023.